Sign In
Buy AGEN
$7.00
+0.0400 (+0.575%)
At Close: Aug 10, 2026
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
07:30am, Monday, 10'th Nov 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights includ
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
01:47pm, Wednesday, 05'th Nov 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financ
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
08:44pm, Tuesday, 21'st Oct 2025
Agenus Inc. (NASDAQ:AGEN ) Shareholder/Analyst Call October 21, 2025 4:00 PM EDT Company Participants Stefanie Perna-Nacar - Chief Communications & Government Relations Officer Garo Armen - Founder, E
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
08:00am, Friday, 17'th Oct 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanc
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
07:48am, Thursday, 16'th Oct 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ESMO2025--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
07:43am, Tuesday, 09'th Sep 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
08:52am, Friday, 05'th Sep 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Globa
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
02:04pm, Thursday, 28'th Aug 2025
Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ColorectalCancer--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates
07:56pm, Monday, 11'th Aug 2025
Agenus (AGEN) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $2.52 per share a year ago.
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
07:30am, Monday, 11'th Aug 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quar
QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration
04:01pm, Thursday, 31'st Jul 2025
QS, CVEO, and AGEN show strong earnings acceleration this month - often a signal of stock price momentum ahead.
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
07:30am, Thursday, 31'st Jul 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results befor
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab i
